very interesting new idea brought to my attention by RHPS today.

http://www.phosphagenics.com/ is the company website and

www.cohenresearch.com has an interesting report on them

with new phosphorylation techniques (inserting a phosphate group into the chemical structure to make it much more readily absorbed into the body), they aim to deliver more effectively previously hard to transmit drugs to the body - Vitamin E (already successfully launched in US), morphine (much smaller amounts needed, so fewer side effects), and others

talks with FDA started on basis of an enhanced delivery rather than enhanced drug action - much simpler process

recently gained Aus government grant of Aus$1.7 to fund Phase I and Pre-Phase II human trials of transdermal morphine delivery

a Material Evaluation Agreement signed with major US pharma to apply PSG's technology to its patented systems

forward PE of 0.54 (yes I did get the decimal point in the right place!)

shares up from about 7p to 12p over last 3 months

listed on Ausraillian Stock Market and London AIM

must be interesting to watch at least. DYOR then do it again to make sure I'm not dreaming.

check it out and ket me know what you think

cheers
SD

forest - no I don't , but isn't the ASX tedious - last year's accounts were barely readable for compliance guff and almost zilch info on the company. I always thought Ozzies were practical, easy-going folk, but ASX verges on the paranoid. Anything of real interest is ont he co's website, not in any formally required reporting.

I guess if the insti bought 3% or more PSG will have to announce this under AIM rules.

Think it more likely to be a strategic stake, rather than an opportunistic bete on soon to be released news, although no evidence to support this.

Another 3.5 years to run on my holding time frame, so plenty of time for one of thie products to really hit the market (apart from their vitE products already selling well).

sd

Thanks. Should get news soon on trials.

Not this soon!

Business Strategy
Financial News
Generics
Legal Actions
Patent Issues
Agency News
Electronic Marketing
Product Marketing News
Cardiovascular
Oncology
Pain & Inflammation
Central Nervous System
Infectious Disease
Contract Research Business
Drug Approvals
Drug Discovery
Drugs In Development
eR&D
Filed For Approval
Trial Results
Regulatory Actions
Warnings
FDA Policy
Investment Banking Healthcare
Medical/Professional


TRIAL RESULTS



Phosphagenics Successfully Delivers Insulin Across the Skin in Humans



No adverse reactions reported



Key points:


* TPM-02/Insulin applied as a gel delivered insulin through the skin and into the bloodstream

* TPM-02/Insulin significantly lowered blood glucose levels

* TPM-02/Insulin did not produce any adverse reactions

* TPM-02 carrier platform has now shown the ability to deliver large molecules (e.g. proteins) through the skin in humans

MELBOURNE, Australia, Aug. 24, 2006--Phosphagenics Limited ("Phosphagenics") (AIM:PSG; ASX: POH) announced today the interim results from its Phase I transdermal insulin clinical trial, demonstrating that it had successfully delivered insulin through the skin in a way that could radically alter patient care for many diabetics around the world, especially those with Type 2.


>From one topical application of TPM-02/Insulin applied as a gel, insulin was shown to safely penetrate the human skin and then be delivered into the blood stream over a sustained period of time.


Dr William Hsu, co-investigator for this trial and clinician at the Joslin Diabetes Center of the Harvard Medical School, Boston, USA, said the trial results are evidence of the safety and tolerability of TPM-02/Insulin and demonstrate that this technology can deliver large molecules such as proteins through the skin.


"The primary objective was to confirm the safety and tolerability of TPM-02/Insulin, and this was achieved with no adverse reactions," Dr Hsu said.


"The trial also demonstrated the ability of TPM-02/Insulin to deliver insulin into the blood stream at levels high enough to produce significant effects. This is a very impressive result, given that it was administered as a single dose to healthy volunteers.


"This technology could eventually transform and expand the world's multi-billion dollar insulin market by providing a non-invasive and effective treatment for many of the world's 194 million diabetics, the majority of which are classified as Type 2," he said.


In the study, 20 healthy male volunteers, aged between 18 and 45, fasted overnight and then randomly received a single dose of TPM-02/Insulin or a placebo gel, applied directly onto the skin. Volunteers were then monitored for a period of 48 hours to assess the primary endpoint of safety.


Conducted at the Centre for Clinical Studies in Melbourne, Australia, and in accordance with ICH GCP standards and under the guidance and supervision of Professor Leon Bach, blood glucose and insulin levels, and the insulin biomarker C-peptide were all measured as secondary endpoints.


"To see TPM-02/Insulin produce a statistically significant and sustained effect on key markers, such as blood glucose concentration, insulin, and C-peptide is very encouraging and warrants significant future development," Dr Hsu said.


Dr Esra Ogru, Executive Director of Research and Development at Phosphagenics, said that this was a milestone for Phosphagenics and allows it to now move rapidly into its next stage of development with TPM-02/Insulin.


"With this success we will now start exploring ways to apply this technology to other pharmaceutical products, as well as developing other routes of administration, such as oral and inhalation," Dr Ogru said.


Phosphagenics Managing Director, Harry Rosen added: "This result supports our recent focus on developing this novel patented technology. We expect this development to enhance international interest in Phosphagenics' technology as it is a key milestone in the delivery of large molecules effectively and safely through the skin

Shares in Phosphagenics jumped 2p to 15.5p after the company unveiled potentially very exciting results from one of its trials. The group said that the interim results from its Phase I transdermal insulin clinical trial demonstrated that it had successfully delivered insulin through the skin in a way that could radically alter patient care for many diabetics around the world, especially those with Type 2. It said that from one topical application of TPM-02/Insulin applied as a gel, insulin was shown to safely penetrate the human skin and then be delivered into the blood stream over a sustained period of time

Great news - patience rewarded!

More to come, long term. A bit in the times today under the headline "smaller stock to watch"

Phosphagenics signs development deal with 'major cosmetics co'
LONDON (AFX) - Australian biotech group Phosphagenics Ltd said it has signed a development deal with what it described as a one of the world's largest cosmetics companies.

The unnamed 'major cosmetics company' will test the feasibility of using Phosphagenics' platform technologies to enhance the delivery of cosmetic compounds.

Phosphagenics has also recently signed development deals with food company Nestle Nutrition and through-the-skin drug delivery company ALZA Corp

sd
radiocast by MD on the following www.boardroomradio.com 30th aug

On the move again up .75 on 65k vol.

This could be massive.

News Releases




12 January 2007











The Manager

Company Announcements Office

The Australian Stock Exchange Limited

Dear Sir



Re: NestlNutrition enters commercial discussions with Phosphagenics





Phosphagenics Ltd (Phosphagenics) (ASX Code: POH) (AIM Code: PSG) announced today that NestlNutrition has exercised its option to finalise the existing commercial agreement to use Phospha-E for the treatment and prevention of metabolic syndrome.



Under the terms of the option agreement, both parties must consent to all public announcements, and further details will be released once Phosphagenics has received Nestle Nutritions consent.









Yours faithfully
Phosphagenics Limited



per Mourice Garbutt
Company Secretary







Contact details:



Mr Harry Rosen

Phosphagenics Ltd

Managing Director

+61 3 9605 5900 or +61 (0)421 322 757

From Self-Trade 8/1/07

Terms: PHOSPHAGENICS LIMITED ENTITLEMENT ISSUE - FOR INFORMATION ONLY
Phosphagenics Limited has announced a Share Purchase Plan whereby shareholders were being
offered the opportunity to purchase between AUD1000.20 and AUD5000.00 worth of new shares. We
have been advised by the registrars to the Company that this is only available to holders of registered
ordinary shares and not holders of Depositary Interests in CRESTtherefore on this occasion the offer is
not available.


Now why couldn't their PR company or their Company Secretary tell me that in respnse to a simple question!

another seemingly faultless step along the way - another year or two of patience required though

http://www.digitallook.com/news/rns/2074014-104201/PSG-Pre-Clinical_Trial_Results.html?ac=209058&username=lukran